{
    "clinical_study": {
        "@rank": "110996", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "ISIS-GCCRRx", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy, safety and tolerability of\n      ISIS-GCCRRx in combination with metformin versus placebo + metformin"
        }, 
        "brief_title": "Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age 18 to 75\n\n          -  BMI greater than or equal to 25\n\n          -  HbA1c greater than or equal to 7.5% and less than or equal to 10.5%\n\n          -  Type 2 Diabetes Mellitus and on stable dose of oral metformin\n\n          -  Agree to conduct home-based (fasted) blood glucose testing as directed\n\n        Exclusion Criteria:\n\n          -  Clinically significant abnormalities in medical history or physical exam\n\n          -  Show evidence of uncorrected hypothyroidism or hyperthyroidism hormone results\n\n          -  History of renal transplantation or renal dialysis\n\n          -  History of liver disease\n\n          -  History of greater than 3 episodes of severe hypoglycemia within 6 months of\n             screening\n\n          -  Use of oral anti-diabetic medication other than metformin within 3 months of\n             screening\n\n          -  Use of medications that may affect plasma glucose levels (including systemic\n             glucocorticoids), systemic steroids, corticosteroids, antiglucocorticoid therapies\n             including mifepristone and ketoconazole (topical cream and systemic),\n             immunosuppressive medications, somatostatin analogues or ACTH therapy within 3 months\n             of screening\n\n          -  History of diabetic ketoacidosis\n\n          -  Current or previous diagnosis of Gilbert's  disease\n\n          -  Any other significant illness or condition that may interfere with the patient\n             participating or completing the study\n\n          -  Inability or unwillingness to comply with protocol or study procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968265", 
            "org_study_id": "ISIS 426115-CS2", 
            "secondary_id": "2013-002172-40"
        }, 
        "intervention": [
            {
                "arm_group_label": "ISIS-GCCRRx", 
                "description": "3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin", 
                "intervention_name": "ISIS-GCCRRx", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Type 2 Diabetes Mellitus", 
            "T2DM"
        ], 
        "lastchanged_date": "October 22, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Red Deer", 
                        "country": "Canada", 
                        "state": "Alberta"
                    }, 
                    "name": "Isis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Penticton", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "Isis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cornwall", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Isis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Courtice", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Isis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sudbury", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Isis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutaneously Once Weekly for 6 Weeks to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin", 
        "overall_contact": {
            "email": "patients@isisph.com", 
            "last_name": "Isis Pharmaceuticals, Inc.", 
            "phone": "1-800-679-4747"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Romania: Ministry of Public Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from Baseline to Week 7", 
            "measure": "The effect of ISIS-GCCRRx on serum fructosamine", 
            "safety_issue": "No", 
            "time_frame": "7 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "By determining the incidence, severity, adverse effects, and changes in laboratory evaluations", 
                "measure": "The safety of ISIS-GCCRRx", 
                "safety_issue": "Yes", 
                "time_frame": "18 Weeks"
            }, 
            {
                "description": "By determining the incidence, severity, adverse effects, and changes in laboratory evaluations", 
                "measure": "The tolerability of ISIS-GCCRRx", 
                "safety_issue": "No", 
                "time_frame": "18 Weeks"
            }
        ], 
        "source": "Isis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}